SI2729143T1 - Uporaba biotina za zdravljenje multiple skleroze - Google Patents

Uporaba biotina za zdravljenje multiple skleroze

Info

Publication number
SI2729143T1
SI2729143T1 SI201330023T SI201330023T SI2729143T1 SI 2729143 T1 SI2729143 T1 SI 2729143T1 SI 201330023 T SI201330023 T SI 201330023T SI 201330023 T SI201330023 T SI 201330023T SI 2729143 T1 SI2729143 T1 SI 2729143T1
Authority
SI
Slovenia
Prior art keywords
biotin
treatment
multiple sclerosis
sclerosis
Prior art date
Application number
SI201330023T
Other languages
English (en)
Inventor
Frederic Sedel
Original Assignee
Assistance Publique Hopitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux De Paris filed Critical Assistance Publique Hopitaux De Paris
Publication of SI2729143T1 publication Critical patent/SI2729143T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201330023T 2012-07-26 2013-04-29 Uporaba biotina za zdravljenje multiple skleroze SI2729143T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR1257254A FR2993780B1 (fr) 2012-07-26 2012-07-26 Methode de traitement de la sclerose en plaque
US13/644,615 US8835487B2 (en) 2012-07-26 2012-10-04 Method of treating multiple sclerosis
EP13719836.2A EP2729143B1 (en) 2012-07-26 2013-04-29 Use of biotin for the treatment of multiple sclerosis
PCT/EP2013/058936 WO2014016003A1 (en) 2012-07-26 2013-04-29 Use of biotin for the treatment of multiple sclerosis

Publications (1)

Publication Number Publication Date
SI2729143T1 true SI2729143T1 (sl) 2015-05-29

Family

ID=47294963

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201330023T SI2729143T1 (sl) 2012-07-26 2013-04-29 Uporaba biotina za zdravljenje multiple skleroze
SI201331768T SI2857019T1 (sl) 2012-07-26 2013-04-29 Postopek zdravljenja multiple skleroze

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201331768T SI2857019T1 (sl) 2012-07-26 2013-04-29 Postopek zdravljenja multiple skleroze

Country Status (25)

Country Link
US (5) US8835487B2 (sl)
EP (2) EP2729143B1 (sl)
JP (1) JP6208235B2 (sl)
KR (1) KR101967502B1 (sl)
CN (2) CN104602689A (sl)
AU (1) AU2013295370B2 (sl)
BR (1) BR112015001562A2 (sl)
CA (1) CA2879434C (sl)
CY (1) CY1116304T1 (sl)
DK (2) DK2857019T3 (sl)
EA (1) EA030478B1 (sl)
ES (3) ES2811074T3 (sl)
FR (1) FR2993780B1 (sl)
HK (1) HK1207583A1 (sl)
HR (1) HRP20150260T1 (sl)
HU (1) HUE024558T2 (sl)
IL (1) IL236790A (sl)
LT (1) LT2857019T (sl)
ME (1) ME02060B (sl)
PL (1) PL2729143T3 (sl)
PT (2) PT2857019T (sl)
RS (1) RS53893B1 (sl)
SI (2) SI2729143T1 (sl)
SM (1) SMT201500057B (sl)
WO (1) WO2014016003A1 (sl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
CA2910717C (en) 2013-04-29 2021-01-26 Assistance Publique - Hopitaux De Paris Biotin for use in treating x-linked adrenoleukodystrophy
CN107531846B (zh) * 2015-02-13 2019-04-30 优迈特株式会社 含氟共聚物和以其作为有效成分的表面改性剂
EP3072513A1 (en) 2015-03-26 2016-09-28 Medday Biotin for treating Amyotrophic lateral sclerosis
US20170135969A1 (en) 2015-11-12 2017-05-18 Jds Therapeutics, Llc Topical arginine-silicate-inositol for wound healing
WO2017086835A1 (ru) * 2015-11-17 2017-05-26 Общество С Ограниченной Ответственностью "Валента-Интеллект" Фармацевтическая композиция, обладающая терапевтическим эффектом в отношении демиелинизирующих заболеваний (варианты)
RU2611415C1 (ru) * 2015-11-17 2017-02-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ ТЕРАПЕВТИЧЕСКИМ ЭФФЕКТОМ В ОТНОШЕНИИ ДЕМИЕЛИНИЗИРУЮЩИХ ЗАБОЛЕВАНИЙ (Варианты)
RU2638803C2 (ru) * 2016-06-09 2017-12-15 Общество С Ограниченной Ответственностью "Валента-Интеллект" Таблетки биотина с замедленным высвобождением и способ их получения
EP3275439A1 (en) * 2016-07-29 2018-01-31 Medday Pharmaceuticals Method for treating hepatic encephalopathy
US11938117B2 (en) 2016-09-01 2024-03-26 Nutrition21, LLC Magnesium biotinate compositions and methods of use
RU2639488C1 (ru) * 2017-04-06 2017-12-21 Общество С Ограниченной Ответственностью "Валента - Интеллект" Фармацевтическая композиция, содержащая биотин, и способ ее получения
WO2020102203A1 (en) * 2018-11-13 2020-05-22 Jds Therapeutics, Llc Treatment of autoimmune disorders, such as relapsing remitting multiple sclerosis and clinically isolated syndrome with biotin compositions
CN112076310A (zh) * 2019-06-14 2020-12-15 苏州融析生物科技有限公司 一种治疗多发性硬化的药物组合物及其制备
EP4076413A1 (en) 2019-12-16 2022-10-26 Nutrition 21, LLC Methods of production of arginine-silicate complexes
JP2023509283A (ja) 2020-01-01 2023-03-08 セラジェネックス リサーチ （インディア） ピーブイティー リミテッド Ａｔｐ効率を向上するための相乗的栄養組成物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3609165A (en) 1968-07-19 1971-09-28 Research Corp 1,3-diazabicyclo {8 3.1.0{9 {0 hex-3-enes
JPH0995448A (ja) 1995-09-29 1997-04-08 Calpis Food Ind Co Ltd:The 血中ビオチン濃度の増加方法およびビオチン含有飲食品
EP0891719A1 (en) * 1997-07-14 1999-01-20 N.V. Nutricia Nutritional composition containing methionine
US5789401A (en) 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
US6664039B1 (en) 1998-10-14 2003-12-16 California Institute Of Technology Methods and compositions for modulating neurodegeneration
UA73492C2 (en) * 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
DE19903241A1 (de) 1999-01-28 2000-08-03 Merck Patent Gmbh Galenische Formulierung
AU2003266287A1 (en) 2002-08-23 2004-03-11 Dsm Ip Assets B.V. Novel nutraceutical compositions comprising biotin
US7709028B2 (en) 2002-09-30 2010-05-04 Daiichi Pharmaceutical Co., Ltd. Particulate product comprising pantethine
DE10341240A1 (de) * 2003-09-08 2005-04-07 Aventis Pharma Deutschland Gmbh Substituierte Thienoimidazole, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
AU2003300167B2 (en) * 2003-12-31 2010-09-16 K-Pax Vitamins, Inc. Nutrient compositions and methods for enhanced effectiveness of the immune system
IL162288A0 (en) * 2004-06-01 2005-11-20 Future Products Man S A Compositions and methods for treating neurodegenerative disorders
BG66011B1 (bg) * 2005-05-25 2010-10-29 Райна Щонова Състав от растителен произход
MX2012007365A (es) 2009-12-23 2012-08-15 Lupin Ltd Composiciones farmaceuticas de liberacion lenta de iloperidona.
FR2993780B1 (fr) 2012-07-26 2015-02-13 Assist Publ Hopitaux De Paris Methode de traitement de la sclerose en plaque
FR2958166B1 (fr) * 2010-04-06 2012-07-13 Assist Publ Hopitaux De Paris Compositions pharmaceutiques fortement dosees en biotine

Also Published As

Publication number Publication date
DK2729143T3 (en) 2015-03-23
CN109908140A (zh) 2019-06-21
PL2729143T3 (pl) 2015-05-29
US10201528B2 (en) 2019-02-12
EP2729143A1 (en) 2014-05-14
US9351961B2 (en) 2016-05-31
EP2857019B1 (en) 2020-05-27
JP2015522630A (ja) 2015-08-06
HUE024558T2 (hu) 2016-02-29
FR2993780B1 (fr) 2015-02-13
CA2879434C (en) 2019-04-23
EA201590270A1 (ru) 2015-11-30
KR20150042799A (ko) 2015-04-21
RS53893B1 (en) 2015-08-31
WO2014016003A1 (en) 2014-01-30
FR2993780A1 (fr) 2014-01-31
CA2879434A1 (en) 2014-01-30
EP2857019A1 (en) 2015-04-08
LT2857019T (lt) 2020-09-10
ES2626079T3 (es) 2017-07-21
PT2729143E (pt) 2015-03-16
HK1207583A1 (en) 2016-02-05
HRP20150260T1 (hr) 2015-05-08
EA030478B1 (ru) 2018-08-31
ES2532364T3 (es) 2015-03-26
US20140348920A1 (en) 2014-11-27
BR112015001562A2 (pt) 2017-07-04
CY1116304T1 (el) 2017-02-08
SI2857019T1 (sl) 2020-10-30
AU2013295370A1 (en) 2015-02-19
DK2857019T3 (da) 2020-08-17
US20190117625A1 (en) 2019-04-25
US20140030331A1 (en) 2014-01-30
US20160324830A1 (en) 2016-11-10
JP6208235B2 (ja) 2017-10-04
ME02060B (me) 2015-05-20
PT2857019T (pt) 2020-07-24
AU2013295370B2 (en) 2017-03-02
ES2811074T3 (es) 2021-03-10
SMT201500057B (it) 2015-05-05
KR101967502B1 (ko) 2019-04-09
EP2729143B1 (en) 2014-12-31
CN104602689A (zh) 2015-05-06
IL236790A (en) 2017-09-28
US8835487B2 (en) 2014-09-16
US20190117626A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
HK1207583A1 (en) Use of biotin for the treatment of multiple sclerosis
HRP20180939T1 (hr) Kombinirana terapija za liječenje multiple skleroze
ZA201406082B (en) Use of ccr3-inhibitors
EP2758780A4 (en) METHOD OF TREATING MULTIPLE SCLEROSIS
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
HK1203054A1 (en) Dinuceloside polyphosphates for the treatment of pain
HK1206283A1 (en) Treatment of multiple sclerosis with anti-cd19 antibody -cd19
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
EP2812190A4 (en) SURFACE TREATMENT COMPOSITION
EP2800554A4 (en) METHOD FOR TREATING MULTIPLE SCLEROSIS AND OTHER DEMYELINISING DISEASES
IL234796B (en) Compounds for the treatment of diseases related to ischemia-reperfusion
HK1210421A1 (en) Use of pregn-4-en-20-yn-3-one for the treatment of depressive disorders -4--20--3-
SI2812351T1 (sl) Farmacevtski sestavek za zdravljenje multiple skleroze
EP2917733A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS
GB201207476D0 (en) pharmaceutical for the treatment of leishmaniasis
IL228464A (en) Quinolone analogues for use in the preparation of MS drugs
GB201210184D0 (en) Formulations of metronidazole for the treatment of pouchitis